Recorded live at AI in GxP West
How Large Enterprises Pilot AI in GxP
From idea to proof of concept: how a global pharmaceutical organization frames, tests, and governs an AI pilot inside a regulated environment, and what it takes to move one past the proof stage.
Stephen J. Cook
Senior Director, GRC CSO and Tech Operations, Global Digital & Tech, GSK
What you'll take away
- Choosing a first use case with a real owner and a measurable outcome
- The evidence a quality organization needs before a pilot is taken seriously
- The risk and accountability questions that decide whether a pilot ever scales
- Where enterprise pilots stall across IT, quality, and the business, and what separates the ones that don't
Complimentary access
Watch the full session
The full recording opens immediately. No membership, no charge.
By requesting access you agree to receive communications from KENX. Unsubscribe anytime.
Full session
On demand
No cost
Access granted
How Large Enterprises Pilot AI in GxP
Sessions like this one are what AI in GxP East is built on. Keep scrolling for 35+ more, live in Raleigh on September 15 and 16.
If you liked this session, there are 35+ more like it at
AI in GxP Europe
Advance Pricing end August 14 · From €1,595 · Register 3, the 4th is freee
OCTOBER 14 AND 15, 2026 · AMSTERDAM
Where the rest of the sessions are.
Two days, 30+ case studies, and a faculty of practitioners who have already put AI into validated environments: governance, multi-agent systems, cleaning validation, cybersecurity, workforce upskilling, and the inspection questions nobody has clean answers to yet.
Featured session · Day One
GSK AI Initiative: Building and Scaling Multi-Agent AI Systems in Practice
Mark Devaney, Director, Chief of Staff, GSK
How GSK is moving beyond pilots to build and scale multi-agent AI systems in real-world regulated operations.
Also on the agenda
Defining Acceptance Criteria for AI Validation
Abhishek Bachchan, Associate Director, IT Security, Risk and Quality, Gilead
How to make an intelligent system testable when the output is not deterministic, and what defensible evidence looks like after the model changes.
“A must-attend event for me in 2026, confirmed through the quality of the speakers and breadth of content. It answered key questions and sparked a wealth of ideas.”
AI IN GXP WEST ATTENDEE
Speaking from inside the regulated world
Who is on the faculty.
Case studies from the quality, validation, and IT leaders accountable when AI touches a GxP system.
Gilead
Noldus Information Technology
Trustbridge Compliance
Jacobs Engineering
TU Dublin
GSK
NOVATEK
CSL Behring
Organon
Pfizer
Körber Pharma Consulting
School of Chemical & BioPharmaceutical Sciences, TU Dublin
HPRA / TU Dublin
Phanero
Körber Pharma
VTI Life Sciences
Roche
See 35 more sessions like this one.
Amsterdam, October 14 and 15. Advance Pricing end August 14.
Manufacturer €1,595, rising to €1,795 after August 14 · Solution provider €1,795, rising to €1,995.
